Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Otsuka recently filed for FDA approval of its anti-APRIL antibody-based IgAN candidate sibeprenlimab, while Biogen has an anti-CD38 antibody called felzartamab in phase 3, raising the prospect of ...